Background: A raised carcinoembryonic antigen (CEA) may be associated with significant pathology during the postoperative follow-up of lung adenocarcinoma. Methods: We reviewed the medical records of 305 patients who underwent surgical resections for primary lung adenocarcinoma at a single institution between April 2006 and February 2013. Results: Preoperative CEA levels were significantly associated with age, smoking history, pathologic stage including pT (pathologic tumor stge), pN (pathologic nodal stage) and overall pathological stage, tumor size and differentiation, pathologically positive total lymph node, N1 and N2 lymph node, N2 nodal station (0/1/2=1.83/2.94/7.21 ng/mL, p=0.019), and 5-year disease-free survival (0.591 in group with normal preoperative CEA levels vs. 0.40 in group with high preoperative CEA levels, p=0.001). Preoperative CEA levels were significantly higher than postoperative CEA levels (p＜0.001, Wilcoxon signed-rank test). Postoperative CEA level was also significantly associated with disease-free survival (p＜0.001). A follow-up serum CEA value of ＞2.57 ng/mL was found to be the appropriate cutoff value for the prediction of cancer recurrence with sensitivity and specificity of 71.4% and 72.3%, respectively. Twenty percent of patients who had recurrence of disease had a CEA level elevated above this cutoff value prior to radiographic evidence of recurrence. Postoperative CEA, pathologic stage, differentiation, vascular invasion, and neoadjuvant therapy were identified as independent predictors of 5-year disease-free survival in a multivariate analysis. Conclusion: The follow-up CEA level can be a useful tool for detecting early recurrence undetected by postoperative imaging studies. The perioperative follow-up CEA levels may be helpful for providing personalized evaluation of lung adenocarcinoma.
INTRODUCTION
Lung cancer is one of the leading causes of death, and adenocarcinoma has been reported to be the most common subtype of lung cancer [1] . Despite having the same cell type and pathologic stages, the clinical prognosis after surgical resection for non-small cell lung cancer varies for each individual [1, 2] . Therefore, personalized evaluation and management for non-small cell lung cancer is essential, and information on other factors as well as the pathologic stage is necessary to evaluate the current status and to predict the accurate prognosis [3] [4] [5] . One such factor can be serum carci- [2, 6] . The serum CEA level has been widely used as a tumor marker and as a predictor of disease progression or recurrence in various types of cancer, particularly in colorectal cancer [7, 8] . Further, some studies have proposed the possibility of the CEA level as a tumor marker or as a predictor after surgical resection for early non-small cell lung cancer [2, 9] . However, the National Comprehensive Cancer Network (NCCN) guidelines for non-small cell lung cancer do not include serum CEA for the evaluation and management of non-small cell lung cancer.
When the preoperative or follow-up CEA level exceeds the normal range, the evaluation and management of these patients tend to be same as those of patients with a normal CEA level. The purpose of the present study is to clarify the significance of the perioperative serum CEA level in predicting the clinical course (i.e., recurrence or metastasis) of a patient with lung adenocarcinoma. We retrospectively compiled the preoperative and follow-up serum CEA levels in all cases of surgical pulmonary resection. These CEA levels were analyzed along with the resulting pathologies and the subsequent clinical courses.
METHODS

1) Materials and methods
We reviewed the medical records of 305 patients who un- The clinical and pathologic stages were determined according to the American Joint Committee on Cancer tumor-nodemetastasis staging method (7th edition). The postoperative follow-up consisted of chest X-ray every 3 months, chest CT, PET-CT, and brain MRI (as needed) every 6 months for 5 years post-surgery. The preoperative and follow-up CEA levels were measured using the chemiluminescent enzyme immunoassay technique. All laboratory tests were carried out by standard methods, using an auto-analyzer (Hitachi 7600-210; Hitachi, Tokyo, Japan) and commercially available assay kits (Sekisui Medical Co. Ltd., Tokyo, Japan). The normal reference value used for our laboratory was a CEA level of 3 ng/mL.
A serum CEA level of less than 3 ng/mL was defined as normal, and follow-up CEA levels were taken every 3 or 6 months. Because there was no definite policy or algorithm for the measurement of the CEA level, we defined each CEA level strictly according to time. The serum CEA level within 1 month before surgery was defined as 'preoperative CEA' and the serum CEA level within 5 months after surgery was defined as 'postoperative CEA.' The serum CEA level within 6 months before recurrence was defined as 'CEA before recurrence.' The serum CEA level at the last follow-up was defined as 'last CEA.' If there were more than two CEA levels in the same period, we chose the higher level. Neoadjuvant or adjuvant therapy was performed by following the NCCN guidelines with consideration of the patient condition.
The clinicopathologic data including imaging studies, serum CEA level, surgical procedure, pathology and mutation studies (EGFR and k-ras), and clinical prognosis were analyzed.
Since most patients were in the early lung cancer stage, the number of cancer-related deaths was small, and various factors after recurrence could influence the overall survival, we carried out a 5-year disease-free survival (DFS, also referred to as recurrence-free survival) study instead of an overall survival study by using recurrence as a primary endpoint to clarify the significance of the serum CEA level. Any recurrence or death due to any cause was included in the recurrence-free survival. Note that DFS is interchangeable with recurrencefree survival under this study design of following up on post
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2) Statistical analysis
Since our data did not have a normal distribution, all data were analyzed using nonparametric statistical methods. The comparisons among subgroups were evaluated using the Mann-Whitney U test, Wilcoxon's signed-rank test, or the Jonckheere-Terpstra test. Association studies were evaluated using Spearman's rho test. DFS rates were calculated using the Kaplan-Meier method, and comparisons of survival curves were carried out by using the log-rank test. To determine the independent prognostic factors of survival, a multivariate analysis was conducted using the Cox proportional hazards model (backward stepwise method). Recurrence or metastasis was defined as an event. The results were analyzed using the PASW SPSS computer software program ver. 18.0 (SPSS Inc., Chicago, IL, USA). A p-value of less than 0.05 was considered statistically significant.
RESULTS
1) Clinicopathologic characteristics
There were 158 patients (81 male and 77 female) who underwent complete resections or intended limited resections; their median age was 64.5 years (range, 33 to 85 years).
Among these 158 patients, 6 (3.8%) patients received neoadjuvant therapy and 36 patients (22.8%) received adjuvant therapy. All patients were pathologically diagnosed with adenocarcinoma or adenocarcinoma combined with another type of cancer, such as adenosquamous carcinoma and mucinous adenocarcinoma. The differentiation grades varied as follows:
well, 81 (51.3%); moderate, 64 (40.5%); and poor, 13 (8.2%).
The pathologic stages were as follows: IA, 94 (59.5%); IB, 35 (22.1%); IIA, 12 (7.6%); IIB, 3 (1.9%); and IIIA, 14 (8.9%). The overall clinicopathologic characteristics of these patients are summarized in Table 1 .
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Preoperative serum carcinoembryonic antigen (CEA) levels according to the pathologic stage. Preoperative CEA levels were positively associated with the overall pathologic stage (p=0.001). In addition, there were more patients in the high preoperative CEA group than in the normal preoperative CEA group at the relatively high pathologic stages (p=0.017, Fisher's exact test).
Fig. 2.
Disease-free survival (i.e., recurrence-free survival) according to preoperative carcinoembryonic antigen (CEA) levels. DFS of the normal preoperative CEA group is significantly higher than that of the high preoperative CEA group (p=0.001, log-rank test).
2) Preoperative carcinoembryonic antigen levels
The incidence of patients with high preoperative CEA levels was 28.5%. Along with the low incidence of a high pre- p=0.001; log-rank test) (Fig. 2) . The results of a univariate analysis of preoperative CEA are summarized in Table 2 .
3) Postoperative carcinoembryonic antigen levels
The incidence of patients with a high postoperative CEA level was 16.5%. There was no significant relationship between postoperative CEA levels and the overall pathologic stage (p=0.062, Jonckheere-Terpstra test) (Fig. 3) . However, the highest postoperative CEA level had a positive association with the pathologic stage (p=0.008, Jonckheere-Terpstra test). Postoperative CEA levels in patients with recurrent disease were significantly higher than the follow-up CEA levels in diseasefree patients (p=0.002, Mann-Whitney U test). Further, the patient group with a normal postoperative CEA level had a longer disease-free interval than the patient group with a high postoperative CEA level (p＜0.001, log-rank test) (Fig. 4) .
4) Relationship between preoperative and postoperative carcinoembryonic antigen levels
Preoperative CEA levels were positively associated with postoperative CEA levels (correlation coefficient=0.789; p＜ 0.001; Spearman's rho test). Preoperative CEA levels were significantly higher than postoperative CEA levels (1.88 vs.
1.46 ng/mL; p＜0.001; Wilcoxon's signed-rank test). However,
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5) Receiver operating characteristic analysis of follow-up carcinoembryonic antigen levels
The cutoff CEA value from the Receiver operating charac- 
6) Follow-up carcinoembryonic antigen levels in groups with high or normal preoperative carcinoembryonic antigen levels
The group with high preoperative CEA levels had significantly higher follow-up CEA levels than the other group with normal preoperative CEA levels in both recurrent and disease-free cases (p＜0.001; p=0.001; Mann-Whitney U test).
In addition, the ROC curve analysis of the serum CEA level in the group with high preoperative CEA levels showed the appropriate cutoff value (＞4.18 ng/mL) for the prediction of cancer recurrence or metastasis with a sensitivity of 85.0%
and a specificity of 83.3% with an area of 0.901 (95% CI, 0.806-0.997), which suggests that follow-up postoperative CEA levels can be used as a potential predictive value for cancer recurrence or metastasis even in patients with high preoperative CEA levels.
7) Follow-up carcinoembryonic antigen levels in patients with or without recurrent disease
Patients with recurrent disease had significantly higher follow-up CEA levels at the time of recurrence than the disease-free patients (p＜0.001, Mann-Whitney U test). Further, the follow-up CEA levels at recurrence were significantly higher than the follow-up CEA levels before recurrence in the same patient (p＜0.001, Wilcoxon's signed-rank test). We found that 20% of the patients who had disease recurrence had an elevated CEA level above the suggested cutoff value (＞2.57 ng/mL) prior to the radiographic evidence of recurrence.
8) Univariate and multivariate prognostic analyses for
5-year disease-free survival
The mean follow-up period of the present study was 35. Table 4 .
DISCUSSION
Despite having the same cell type and pathologic stages, the clinical prognosis after surgical resection for non-small cell lung cancer varies for each individual [1, 2] . This may be due to inaccurate or insufficient evaluation, and heterogeneous characteristics of the patients with the same stage of disease.
We routinely evaluate the preoperative cancer staging and the postoperative status through imaging studies, such as chest CT and PET-CT. However, there may be unidentified or missed metastases. Even if the staging is correct, the patients' heterogeneity in the same stage can result in unexpected recurrence or metastases. Therefore, we need modalities for additional evaluation to improve the prognosis of these patients [10, 11] .
One modality can be the serum CEA levels [2, 6] . Serum CEA is one of the most widely used markers in various canJae Jun Kim, et al
cers, particularly in the case of colorectal cancer [7, 8] . The possibility of using serum CEA levels as a tumor marker or a predictor has been reported after the surgical resection of early non-small cell lung cancer [6, 9] . Our study showed that the pre-and postoperative and follow-up CEA levels are strongly associated with the current status and prognosis of patients in all surgical stages following surgical resection.
The preoperative CEA levels were generally higher with more progressive cancer before surgery. Patients with higher preoperative CEA levels had a significantly shorter 5-year DFS than those with normal preoperative CEA levels. There was a significant decrease in the CEA level after surgery, which can reflect the reduction or disappearance of the cancer load and extent. Patients with higher postoperative CEA levels also had a significantly shorter 5-year DFS than patients with normal postoperative CEA levels, which can suggest the possibility of the cancer remaining after surgery in patients with relatively high postoperative CEA levels [12] . The follow-up CEA level at recurrence was significantly higher than both the CEA level before recurrence in the same patient and the median follow-up CEA level in the disease-free patients.
Therefore, this may suggest that the possibility of recurrence or metastasis may exist in asymptomatic, average-risk patients with an elevated follow-up CEA level. In addition, we found that 20% of the patients who had recurrence of disease had an elevated CEA level prior to the radiographic evidence of recurrence, which suggests the possibility that CEA may provide earlier detection of recurrence or metastases than imaging studies in some cases. The ROC curve analysis showed that follow-up CEA levels can be a potential predictor of cancer recurrence or metastasis, and follow-up CEA levels were considered to be helpful in detecting early recurrence, which was not detected by imaging studies. At present, the serum CEA level is not included in the NCCN guidelines.
Nevertheless, follow-up CEA levels, as well as preoperative CEA levels, can be helpful prognostic indicators in patients who undergo resections for lung adenocarcinoma [12, 13] .
Previous studies have also reported that the independent prognostic factors of the 5-year DFS after surgery are as follows:
the pathologic stage, neoadjuvant and adjuvant therapy, differentiation, vascular invasion, lymphatic invasion, preoperative CEA levels, and the extent of resection and gene mutation [4, 13, 14] . Similarly, the present study showed that the postoperative CEA levels, the pathologic stage, differentiation, vascular invasion, and neoadjuvant therapy were the prognostic factors of the 5-year DFS in the multivariate analysis.
We tentatively suggest that the CEA levels, including the preoperative and follow-up CEA levels, should be included in the NCCN guidelines for more appropriate decision making and management. Patients with relatively high preoperative or follow-up CEA levels need to be evaluated and managed more carefully, even in patients with stage IA or IB disease [6, 14] . After the completion of adjuvant therapy without any detection of recurrence or metastasis by imaging studies, additional management may be needed if a patient has elevated follow-up CEA levels [9, 10] . A number of previous studies have reported that the serum CEA level was closely associated with EGFR or k-ras mutation [7, 15, 16] . However, our study found no association between these factors. In contrast to our expectations, neoadjuvant therapy had a negative prognostic effect on the 5-year DFS in the multivariate analysis, which may be due to the small sample size, and on patients having more advanced disease, and led to poor prognosis in patients who required neoadjuvant therapy. The extent of resection had no effect on the 5-year DFS, which may be due to the patients undergoing limited resection at the early stages, and having less invasive disease and a good prognosis.
This study has several limitations. The first is its retrospective design. The second limitation is the small sample size, not having a normal distribution of the data, and the short observation period. The most common type of lung cancer identified during the early study period was squamous cell carcinoma, and compared to the present, regular health check-ups were less common in the past. Hence, most of our data were registered in the later study period and most pa- Nevertheless, this study shows strong evidence of associations between serum CEA levels and disease status and prognosis after surgery. Therefore, the measurement of CEA levels may improve the evaluation of the current status and prognosis after surgery for lung adenocarcinoma patients.
Moreover, individualized treatment for lung adenocarcinoma can be achieved.
In conclusion, although the CEA level cannot be a preoperative screening test for lung adenocarcinoma due to the low incidence of CEA elevation, the preoperative CEA levels and follow-up CEA levels can be used as prognostic factors for lung adenocarcinoma after surgery. The follow-up CEA level can be a useful tool for detecting early recurrence undetected by postoperative imaging studies. Therefore, preoperative and postoperative follow-up CEA levels may be helpful for providing personalized evaluation and management.
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